Land: USA
Språk: engelska
Källa: NLM (National Library of Medicine)
DEXRAZOXANE HYDROCHLORIDE (UNII: 5346058Q7S) (DEXRAZOXANE - UNII:048L81261F)
Eugia US LLC
PRESCRIPTION DRUG
Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2)] . Do not use dexrazoxane for injection with non-anthracycline chemotherapy regimens. Risk Summary Dexrazoxane can cause fetal harm when administered to pregnant women. Dexrazoxane administration resulted in maternal toxicity, embryotoxicity and teratogenicity in rats and rabbits at doses significantly lower than the clinically recommended dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Warnings and Precautions (5.5)] . Animal Data Dexrazoxane resulted in maternal toxicity in rats
Dexrazoxane for injection is available in the following strengths as sterile, pyrogen-free lyophilizates. NDC 55150-434-01 250 mg single-dose vial with a green flip-top seal, packaged in single vial packs. (This package also contains a 25 mL vial of 0.167 Molar (M/6) sodium lactate injection, USP.) NDC 55150-437-01 500 mg single-dose vial with a blue flip-top seal, packaged in single vial packs. (This package also contains a 50 mL vial of 0.167 Molar (M/6) sodium lactate injection, USP.) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Reconstituted solutions of dexrazoxane for injection are stable for 6 hours at controlled room temperature or under refrigeration, 2° to 8°C (36° to 46°F). Discard unused solutions. Follow special handling and disposal procedures. The vial stopper is not made with natural rubber latex.
Abbreviated New Drug Application
DEXRAZOXANE- DEXRAZOXANE EUGIA US LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DEXRAZOXANE FOR INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DEXRAZOXANE FOR INJECTION. DEXRAZOXANE FOR INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1995 INDICATIONS AND USAGE Dexrazoxane for injection is a cytoprotective agent indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use dexrazoxane for injection with doxorubicin initiation. (1) DOSAGE AND ADMINISTRATION Reconstitute vial contents and dilute before use. (2.3) Administer dexrazoxane for injection by slow I.V. push or rapid drip intravenous infusion from a bag. (2.1, 2.3) The recommended dosage ratio of dexrazoxane for injection to doxorubicin is 10:1 (e.g., 500 mg/m dexrazoxane for injection to 50 mg/m doxorubicin). Do not administer doxorubicin before dexrazoxane for injection. (2.1) Reduce dose by 50% for patients with creatinine clearance < 40 mL/min. (2.2, 8.7) DOSAGE FORMS AND STRENGTHS 250 mg or 500 mg single-dose vials as sterile, pyrogen-free lyophilizates. (3) CONTRAINDICATIONS Dexrazoxane for injection should not be used with non-anthracycline chemotherapy regimens. (4) WARNINGS AND PRECAUTIONS Myelosuppression: Dexrazoxane may increase the myelosuppresive effects of chemotherapeutic agents. Perform hematological monitoring. (5.1) Embryo-Fetal Toxicity: Can cause fetal harm. Advise female patients of reproductive potential of the potential hazard to the fetus. (5.5, 8.1) ADVERSE REACTIONS In clinical studies, dexrazoxane was administered to patients also receiving chemotherapeutic agents for cancer. Pain on injection was observed more frequently in patients receiving dexrazoxane versus placebo. (6.1) TO REPORT SUSPECT Läs hela dokumentet